Plus Therapeutics Relocates Principal Executive Offices

Ticker: PSTV · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1095981

Plus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyPlus Therapeutics, Inc. (PSTV)
Form Type8-K
Filed DateNov 17, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $1.00 m, $1.00
Sentimentneutral

Sentiment: neutral

Topics: corporate-actions, filing-update

TL;DR

PLUS THERAPEUTICS moved offices to Houston, TX.

AI Summary

On November 17, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2710 Reed Road, Suite 160, Houston, Texas 77051. The company was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.

Why It Matters

A change in principal executive offices can signal operational shifts or strategic realignments within the company.

Risk Assessment

Risk Level: low — This filing primarily concerns a change of address for the company's principal executive offices, which is a routine administrative event.

Key Players & Entities

  • PLUS THERAPEUTICS, INC. (company) — Registrant
  • CYTORI THERAPEUTICS, INC. (company) — Former company name
  • MACROPORE INC (company) — Former company name
  • 2710 Reed Road, Suite 160, Houston, Texas 77051 (location) — New principal executive offices
  • November 17, 2025 (date) — Date of report

FAQ

What is the new address for PLUS THERAPEUTICS, INC.'s principal executive offices?

The new address for the principal executive offices is 2710 Reed Road, Suite 160, Houston, Texas 77051.

When was this 8-K report filed?

This 8-K report was filed on November 17, 2025.

What were some of the former names of PLUS THERAPEUTICS, INC.?

The company was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.

In which state is PLUS THERAPEUTICS, INC. incorporated?

PLUS THERAPEUTICS, INC. is incorporated in Delaware.

What is the IRS Employer Identification Number (EIN) for PLUS THERAPEUTICS, INC.?

The IRS Employer Identification Number for PLUS THERAPEUTICS, INC. is 33-0827593.

Filing Stats: 815 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2025-11-17 07:35:06

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 PSTV The Nasdaq Capital Market Ind
  • $1.00 m — q Staff") to regain compliance with the $1.00 minimum bid price bid requirement set for
  • $1.00 — Company's common stock had fallen below $1.00 per share for 30 consecutive business d

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of the issuer dated November 17, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 17, 2025 PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.